Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MiMedx Group (MDXG)
NASDAQ:MDXG
Holding MDXG?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.07Last Year’s EPS
$0.32Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: 59.93%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While the company achieved revenue growth, maintained strong cash flow, and saw positive developments with new products like HELIOGEN, it faced significant challenges from reimbursement issues and declines in surgical sales. The sentiment is cautiously optimistic with expectations for future growth.Company Guidance
During the MiMedx Q3 2024 earnings call, the company reported a 3% year-over-year increase in net sales, totaling $84 million, and maintained a strong gross profit margin of 82%. Adjusted EBITDA was $18 million, representing 22% of net sales. The company ended the quarter with a cash balance of $89 million, an increase of $20 million. MiMedx expressed optimism about future growth, despite challenges related to Medicare reimbursement issues, and raised its full-year revenue growth guidance to high single digits. The company highlighted the successful market release of HELIOGEN, a new xenograft product, and continued strong performance in its international business. CEO Joe Capper also emphasized ongoing efforts to address the reimbursement environment and highlighted strategic priorities, including product innovation and expanding their footprint in the surgical market.Year-Over-Year Revenue Growth
Net sales grew by $2 million or 3% to $84 million in the third quarter, in line with expectations.
Strong Cash Position
Cash increased by $20 million in the quarter, ending with $89 million, doubling the net cash position from the previous year.
Positive Developments on HELIOGEN
Continued the market release of HELIOGEN, with positive feedback and expected material contributions in 2025.
Successful Product Expansion in Japan
EPIFIX business in Japan posted high growth, with nearly 800 physicians trained and sales expected to grow nearly threefold from 2023.
Strong Adjusted EBITDA
Adjusted EBITDA was $18 million or 22% of net sales, representing an increase over the prior year period.
---
MDXG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDXG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $5.69 | $6.85 | +20.39% |
| Jul 30, 2024 | $7.59 | $7.45 | -1.84% |
| Apr 30, 2024 | $6.16 | $7.31 | +18.67% |
| Feb 28, 2024 | $8.20 | $8.16 | -0.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MiMedx Group (MDXG) report earnings?
MiMedx Group (MDXG) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is MiMedx Group (MDXG) earnings time?
MiMedx Group (MDXG) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXG EPS forecast?
MDXG EPS forecast for the fiscal quarter 2024 (Q4) is $0.07.
---